Boehringer and ZEISS partnership eye diseases Boehringer and ZEISS partnership eye diseases Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
Boehringer Ingelheim and Fraunhofer partnership Boehringer Ingelheim and Fraunhofer partnership Boehringer Ingelheim and Fraunhofer IME launch collaboration which aims to develop sustainable animal health products
expanded-collaboration-MD-Anderson expanded-collaboration-MD-Anderson The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
BI increases commitments to sustainable development BI increases commitments to sustainable development At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
European Metacam® indication expanded to guinea pigs European Metacam® indication expanded to guinea pigs Boehringer Ingelheim adds a new species to its Metacam® brand in Europe, expanding the indications of this widely-used medicine to guinea pigs.
Fight against COVID-19 pandemic Fight against COVID-19 pandemic Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Phase 3 studies survodutide obesity and overweight Phase 3 studies survodutide obesity and overweight Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Clinical-phase2-trials-NASH-and-obesity Clinical-phase2-trials-NASH-and-obesity Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Partnership for first-in-class cancer and CRM treatments Partnership for first-in-class cancer and CRM treatments Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
Partnership with IBM to accelerate new antibody therapies Partnership with IBM to accelerate new antibody therapies Boehringer Ingelheim collaborates with IBM to advance generative AI and foundation models for therapeutic antibody development
Acquisition expands research in cancer immunology Acquisition expands research in cancer immunology Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
FRONTLINE® becomes Brand of the Year 2021-22 FRONTLINE® becomes Brand of the Year 2021-22 FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
Introducing Karl and Klara Kidney Introducing Karl and Klara Kidney Kidney disease and type 2 diabetes are closely linked, and share many of the same risk factors and pathological pathways
Heart Diseases in humans and animals Heart Diseases in humans and animals Humans and animals are more alike than different. Having a heart disease can affect us similarly, and the way to prevent it can work for all as well.
SPEVIGO approved expanded indications China US SPEVIGO approved expanded indications China US SPEVIGO® approved for expanded indications in China and the US
Two new claims for Nexgard range in EU and Australia Two new claims for Nexgard range in EU and Australia Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
FRONTLINE becomes Brand of the Year 2019-2020 FRONTLINE becomes Brand of the Year 2019-2020 FRONTLINE becomes ‘Brand of the Year’ 2019-2020 in World Branding Awards
FDA Grants Breakthrough Status to Schizophrenia Treatment FDA Grants Breakthrough Status to Schizophrenia Treatment Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
Bringing focus to biliary tract and pancreatic cancers Bringing focus to biliary tract and pancreatic cancers The Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced biliary tract and pancreatic cancers.
Acquisition Saint-Herblon site and Coophavet brand Acquisition Saint-Herblon site and Coophavet brand Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production site
All the same, yet different – Ethnic Equality Month All the same, yet different – Ethnic Equality Month Mohammed Samy, Human Pharma Marketing Team Lead from Amsterdam explains how ethnic diversity creates collective strength and sustainable growth
Heart murmur in dogs: symptoms and how to treat it Heart murmur in dogs: symptoms and how to treat it Monitoring your dog’s heart can save its life
“Rapid progress towards clinical candidates” “Rapid progress towards clinical candidates” Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
How to create an Ariba standard account processing a purchas How to create an Ariba standard account processing a purchas